LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

LENZ Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$3.30+0.03 (+0.92%)

Close on Oct 19, 2026

Community

Notes and questions about LENZ Therapeutics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in LENZ Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-29 reverse split on May 8, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LENZ.

Revenue growth329.5% · median -8.1%

Gross margin86.9% · median 92.7%

Operating margin-631.7% · median -396.8%

Net margin-586.7% · median -366.4%

Advertisement
300 × 250